John Davis Sells 2,784 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 2,784 shares of Artivion stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $38.02, for a total value of $105,847.68. Following the transaction, the insider directly owned 206,522 shares in the company, valued at approximately $7,851,966.44. This trade represents a 1.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Artivion Price Performance

NYSE AORT opened at $38.41 on Thursday. The company has a 50 day simple moving average of $41.42 and a 200-day simple moving average of $42.92. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 192.06 and a beta of 1.60. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion’s revenue was up 19.2% compared to the same quarter last year. Equities research analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Wall Street Analyst Weigh In

Several analysts recently issued reports on AORT shares. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Artivion in a research report on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Canaccord Genuity Group lowered their price target on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Finally, Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.97.

Institutional Investors Weigh In On Artivion

A number of hedge funds have recently bought and sold shares of AORT. Summit Partners Public Asset Management LLC acquired a new stake in shares of Artivion in the fourth quarter valued at about $39,401,000. Invesco Ltd. lifted its position in shares of Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after purchasing an additional 748,119 shares during the last quarter. Champlain Investment Partners LLC bought a new stake in Artivion during the 3rd quarter valued at approximately $17,912,000. Goldman Sachs Group Inc. grew its holdings in Artivion by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after buying an additional 317,518 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in Artivion by 235.5% in the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after buying an additional 313,446 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.